Photo from wikipedia
Key Points Question Is targeted gene testing cost-effective in patients with metastatic gastrointestinal stromal tumor? Findings This economic evaluation developed a Markov model to examine the cost-effectiveness of targeted gene… Click to show full abstract
Key Points Question Is targeted gene testing cost-effective in patients with metastatic gastrointestinal stromal tumor? Findings This economic evaluation developed a Markov model to examine the cost-effectiveness of targeted gene testing with tailored imatinib dosing for patients with gastrointestinal stromal tumor based on KIT exon variation status. The model found that targeted gene testing was cost-effective, with an incremental cost-effectiveness ratio of $92 100, compared with empirical treatment with imatinib. Meaning These findings support the cost-effectiveness of widespread adoption of genetic testing for patients newly diagnosed with metastatic gastrointestinal stromal tumor.
Journal Title: JAMA Network Open
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!